You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

395 Results
Document
Dec 1969
Document
Dec 1969
Document
Sep 2024
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Drugs Used:
oxaliplatin,
leucovorin,
irinotecan,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
trastuzumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
*/
Document
New
Jan 2025
*/
Senior Scientist, Acute and Hospital-Based Care, Ontario Health Senior Scientist michelle.cotterchio@ontariohealth.ca
Chercheuse principale, Soins aigus et hospitaliers, Santé Ontario Chercheuse principalemichelle.cotterchio@ontariohealth.ca

Pages